title: Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.
abstract: Individuals with the neurofibromatosis type 1 (NF1) inherited cancer syndrome exhibit neuronal dysfunction that predominantly affects the CNS. In this report, we demonstrate a unique vulnerability of CNS neurons, but not peripheral nervous system (PNS) neurons, to reduced Nf1 gene expression. Unlike dorsal root ganglion neurons, Nf1 heterozygous (Nf1+/-) hippocampal and retinal ganglion cell (RGC) neurons have decreased growth cone areas and neurite lengths, and increased apoptosis compared to their wild-type counterparts. These abnormal Nf1+/- CNS neuronal phenotypes do not reflect Ras pathway hyperactivation, but rather result from impaired neurofibromin-mediated cAMP generation. In this regard, elevating cAMP levels with forskolin or rolipram treatment, but not MEK (MAP kinase kinase) or PI3-K (phosphatidylinositol 3-kinase) inhibition, reverses these abnormalities to wild-type levels in vitro. In addition, Nf1+/- CNS, but not PNS, neurons exhibit increased apoptosis in response to excitotoxic or oxidative stress in vitro. Since children with NF1-associated optic gliomas often develop visual loss and Nf1 genetically engineered mice with optic glioma exhibit RGC neuronal apoptosis in vivo, we further demonstrate that RGC apoptosis resulting from optic glioma in Nf1 genetically engineered mice is attenuated by rolipram treatment in vivo. Similar to optic glioma-induced RGC apoptosis, the increased RGC neuronal death in Nf1+/- mice after optic nerve crush injury is also attenuated by rolipram treatment in vivo. Together, these findings establish a distinctive role for neurofibromin in CNS neurons with respect to vulnerability to injury, define a CNS-specific neurofibromin intracellular signaling pathway responsible for neuronal survival, and lay the foundation for future neuroprotective glioma treatment approaches.
authors.affiliation: Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
authors.forename: Jacquelyn A
authors.initials: JA
authors.lastname: Brown
authors.forename: Scott M
authors.initials: SM
authors.lastname: Gianino
authors.forename: David H
authors.initials: DH
authors.lastname: Gutmann
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics; D002470:Cell Survival / Q000235:genetics; D002478:Cells, Cultured; D002490:Central Nervous System / Q000378:metabolism* / Q000473:pathology; D000242:Cyclic AMP / Q000096:biosynthesis / Q000172:deficiency* / Q000235:genetics; D006580:Genetic Carrier Screening; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D009409:Nerve Crush; D009456:Neurofibromatosis 1 / Q000235:genetics* / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism* / Q000473:pathology; D012165:Retinal Ganglion Cells / Q000378:metabolism / Q000473:pathology
chemical_list: D000242:Cyclic AMP
references.citation: J Cell Biol. 1993 May;121(3):665-72
references.pmid: 8486743
references.citation: Curr Opin Cell Biol. 1990 Feb;2(1):80-5
references.pmid: 2139335
references.citation: Nature. 1992 Apr 23;356(6371):713-5
references.pmid: 1570015
references.citation: Curr Biol. 2005 Nov 8;15(21):1961-7
references.pmid: 16271875
references.citation: J Neuropathol Exp Neurol. 2009 May;68(5):542-51
references.pmid: 19525901
references.citation: Neurosci Lett. 1999 Jan 8;259(2):111-4
references.pmid: 10025570
references.citation: Mol Cell Biol. 1997 Feb;17(2):862-72
references.pmid: 9001241
references.citation: Cell. 2008 Oct 31;135(3):549-60
references.pmid: 18984165
references.citation: J Invest Dermatol. 1999 Jun;112(6):835-42
references.pmid: 10383727
references.citation: J Neurosci Res. 1994 Jun 15;38(3):248-58
references.pmid: 7932862
references.citation: Vis Neurosci. 2005 Sep-Oct;22(5):661-76
references.pmid: 16332277
references.citation: Ann Neurol. 1997 Feb;41(2):143-9
references.pmid: 9029062
references.citation: Neurology. 1997 Apr;48(4):1121-7
references.pmid: 9109916
references.citation: Cell. 1995 Sep 8;82(5):733-42
references.pmid: 7671302
references.citation: J Biol Chem. 2001 Mar 9;276(10):7240-5
references.pmid: 11080503
references.citation: Cancer Res. 2007 Sep 15;67(18):8588-95
references.pmid: 17875698
references.citation: Nat Neurosci. 2002 Feb;5(2):95-6
references.pmid: 11788835
references.citation: Neuron. 2004 Jun 10;42(5):717-30
references.pmid: 15182713
references.citation: Mol Cell Neurosci. 2003 Jan;22(1):49-61
references.pmid: 12595238
references.citation: Cell. 1992 Apr 17;69(2):265-73
references.pmid: 1568246
references.citation: Circulation. 2007 Nov 6;116(19):2148-56
references.pmid: 17967772
references.citation: Glia. 2007 Jan 1;55(1):1-12
references.pmid: 16998865
references.citation: Mol Biol Cell. 2009 Feb;20(4):1167-79
references.pmid: 19109430
references.citation: J Exp Med. 2000 Jan 3;191(1):181-8
references.pmid: 10620616
references.citation: Cell Stem Cell. 2007 Oct 11;1(4):443-57
references.pmid: 18371380
references.citation: Genes Dev. 2001 Apr 1;15(7):859-76
references.pmid: 11297510
references.citation: Neuron. 1990 Sep;5(3):373-81
references.pmid: 2169272
references.citation: J Neurosci. 2003 Aug 6;23(18):7207-17
references.pmid: 12904481
references.citation: J Neurosci. 2007 Feb 21;27(8):2124-34
references.pmid: 17314307
references.citation: Hum Mol Genet. 2007 May 1;16(9):1098-112
references.pmid: 17400655
references.citation: Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2442-9
references.pmid: 12091449
references.citation: J Dev Behav Pediatr. 1986 Jun;7(3):175-9
references.pmid: 3088045
references.citation: Hum Mol Genet. 2008 Oct 1;17(19):2956-66
references.pmid: 18614544
references.citation: J Neurosci Res. 2003 Dec 1;74(5):726-35
references.pmid: 14635223
references.citation: Mol Cell Neurosci. 2000 Apr;15(4):398-407
references.pmid: 10845775
references.citation: Exp Neurol. 2004 Apr;186(2):124-33
references.pmid: 15026251
references.citation: Am J Physiol. 1993 Aug;265(2 Pt 1):C422-31
references.pmid: 8396326
references.citation: J Biol Chem. 1999 Sep 3;274(36):25842-8
references.pmid: 10464325
references.citation: J Neurosci. 2003 Oct 1;23(26):8949-54
references.pmid: 14523097
references.citation: J Neurosci. 1998 Dec 15;18(24):10420-8
references.pmid: 9852579
references.citation: Development. 2005 Dec;132(24):5577-88
references.pmid: 16314489
references.citation: Am J Med Genet. 1999 Mar 26;89(1):45-52
references.pmid: 10469436
references.citation: Dev Neurobiol. 2009 Sep 1;69(10):633-46
references.pmid: 19513995
references.citation: Neurology. 2005 Oct 11;65(7):1037-44
references.pmid: 16217056
references.citation: Neuron. 1988 Nov;1(9):791-803
references.pmid: 2908449
references.citation: Dev Med Child Neurol. 1995 May;37(5):427-36
references.pmid: 7768342
references.citation: Cancer Res. 2003 Dec 15;63(24):8573-7
references.pmid: 14695164
references.citation: Nature. 2002 Jan 31;415(6871):526-30
references.pmid: 11793011
references.citation: J Biochem. 2009 Jun;145(6):771-81
references.pmid: 19254925
references.citation: Cancer Res. 2007 May 15;67(10):4790-9
references.pmid: 17510408
references.citation: FASEB J. 2006 Apr;20(6):785-7
references.pmid: 16467371
references.citation: Cancer Res. 2005 Jan 1;65(1):236-45
references.pmid: 15665300
references.citation: Blood. 2008 Dec 1;112(12):4646-54
references.pmid: 18768391
references.citation: Mol Cell Endocrinol. 1997 Jun 20;130(1-2):93-100
references.pmid: 9220025
references.citation: Nat Genet. 1996 Feb;12(2):144-8
references.pmid: 8563751
references.citation: J Assoc Res Otolaryngol. 2001 Dec;2(4):377-87
references.pmid: 11833610
references.citation: Neuro Oncol. 2007 Oct;9(4):430-7
references.pmid: 17704361
references.citation: Methods Mol Biol. 2007;356:427-34
references.pmid: 16988421